论文部分内容阅读
目的用杂交瘤技术制备脐血树突状细胞(DC)和食管癌细胞的融合疫苗,观察其在体内诱导抗肿瘤免疫反应。方法分离脐血CD34+干细胞并诱导扩增为成熟DC,并与EC109细胞经聚乙二醇(PEG)法融合;免疫磁珠法筛选EC109-DC;重建SCID小鼠免疫功能;体内保护抗肿瘤免疫保护实验。结果①融合疫苗可体外生长,形状以不规则形为主,核仁大、细胞边缘可见突起;②重建SCID小鼠免疫功能实验中PBL组均检测到人IgG的存在,与PBS组相比较有显著意义(P<0.05);③在免疫保护中,经融合瘤苗免疫的小鼠,肿瘤潜伏期较对照组明显延长(P<0.05),肿瘤大小和肿瘤重量均明显小于对照组(P<0.05)。结论①重建SCID小鼠免疫功能实验中PBL组均检测到人IgG的存在,提示免疫重建成功;②融合瘤苗对EC109细胞的攻击有明显的抵抗作用。
Objective To prepare fusion vaccine of dendritic cells (DCs) and esophageal cancer cells by hybridoma technique and observe its anti-tumor immune response in vivo. Methods Cord blood CD34 + stem cells were isolated and induced to proliferate into mature DCs and fused with EC109 cells by polyethylene glycol (PEG) method. EC109-DC was screened by immunomagnetic beads method. The immune function of SCID mice was reconstructed. The anti-tumor immunity Protect the experiment. Results ① The fusion vaccine could grow in vitro with irregular shape, large nucleoli and prominent cells at the edge of the cell. ② The immune function of SCID mice was detected in human PBL group, compared with PBS group (P <0.05). ③In immune protection, the mice immunized with the fusion vaccine had significantly longer incubation period (P <0.05), tumor size and tumor weight than those in the control group (P <0.05) ). Conclusions ① The immune function of SCID mice in PBL group were detected in the presence of human IgG, suggesting that successful immune reconstitution; ② fusion tumor vaccine EC109 cells were significantly resistant to the attack.